GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » 5-Year Yield-on-Cost %

CytoMed Therapeutics (CytoMed Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of May. 28, 2024)


View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics 5-Year Yield-on-Cost %?

CytoMed Therapeutics's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for CytoMed Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



GDTC's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.8
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of CytoMed Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, CytoMed Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoMed Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's 5-Year Yield-on-Cost % falls into.



CytoMed Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of CytoMed Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

CytoMed Therapeutics  (NAS:GDTC) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


CytoMed Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoMed Therapeutics (CytoMed Therapeutics) Business Description

Traded in Other Exchanges
Address
1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.
Executives
Chee Kong Choo director, 10 percent owner COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng director, officer: CSO and CMO 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang 10 percent owner 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan director, officer: Chief Operating Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd 10 percent owner 18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee director, officer: Chief Clinical Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh director 1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544